Targeting CD133 antigen in cancer

Bibliography

• Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90:5013-21
   PubMed Web of Science ®Google Scholar
• Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA 1997;94:12425-30
   PubMed Web of Science ®Google Scholar
• Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-12
   PubMed Web of Science ®Google Scholar
• Scadden DT. The stem-cell niche as an entity of action. Nature 2006;441:1075-79
   PubMed Web of Science ®Google Scholar
• Werbowetski-Ogilvie TE, Bhatia M. Pluripotent human stem cell lines: what we can learn about cancer initiation. Trends Mol Med 2008;14:323-32
   PubMed Web of Science ®Google Scholar
• Neuzil J, Stantic M, Zobalova R, et al. Tumour-initiating cells vs. cancer stem cells and CD133: what’:s in a name? Biochem Biophys Res Commun 2007;355:855-59
   PubMed Web of Science ®Google Scholar
• Gou Y, Follo K, Geiger M, et al. Side population cells from different precursor compartment. J Hematother Stem Cell Res 2003;12:71-82
   PubMedGoogle Scholar
• Clarke MF, Dick SE, Dirks PB, et al. Cancer stem cells – perspectives on current status and future directions: AACR Workshop on cancer stem. Cells 2006;66:9339-44
   Google Scholar
• Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007;58:267-84
   PubMed Web of Science ®Google Scholar
• Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5:738-43
   PubMed Web of Science ®Google Scholar
• Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma. Mol Cancer 2006;5:67, published online 2 December 2006, doi:10.1186/1476-4598-5-67
   PubMed Web of Science ®Google Scholar
• Ma S, Lee TK, Zheng BJ, et al. CD133 + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-58
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008;8:545-54
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401
   PubMed Web of Science ®Google Scholar
• Zeppernick F, Ahmadi R, Campos B, et al. Stem cells marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-29
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-15
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Bonanno G, Pierelli L, et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 2008;18:506-14
   PubMed Web of Science ®Google Scholar
• Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-23
   PubMed Web of Science ®Google Scholar
• Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008;26:3008-17
   PubMed Web of Science ®Google Scholar
• Corbeil D, Roper K, Weigmann A, Huttner WB. AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? Blood 1998;91:2625-26
   PubMed Web of Science ®Google Scholar
• Miraglia S, Godfrey W, Buck D. A response to AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? Blood 1998;91:4390-91
   PubMed Web of Science ®Google Scholar
• Shmelkov SV, Jun L, St Clair R, et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 2004;103:2055-61
   PubMed Web of Science ®Google Scholar
• Florek M, Haase M, Marzesco AM, et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005;319:15-26
   PubMed Web of Science ®Google Scholar
• Corbeil D, Roper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000;275:5512-20
   PubMed Web of Science ®Google Scholar
• Bhatia M. AC133 expression in human stem cells. Leukemia 2001;15:1685-88
   PubMed Web of Science ®Google Scholar
• Immervoll H, Hoem D, Sakariassen PO, et al. Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 2008;8:1-14
   PubMed Web of Science ®Google Scholar
• Fargeas CA, Florek M, Huttner WB, Corbeil D. Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins. J Biol Chem 2003;278:8586-96
   PubMed Web of Science ®Google Scholar
• Fargeas CA, Joester A, Missol-Kolka E, et al. Identification of novel prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci 2004;117:4301-11
   PubMed Web of Science ®Google Scholar
• Fargeas CA, Huttner WB, Corbeil D. Nomenclature of prominin-1 (CD133) splice variants – an update. Tissue Antigens 2007;69:602-6
   PubMed Web of Science ®Google Scholar
• Yu Y, Flint A, Dvorin EL, Bischoff J. AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 2002;277:20711-16
   PubMed Web of Science ®Google Scholar
• Roper K, Corbeil D, Huttner WB. Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane. Nat Cell Biol 2000;2:582-92
   PubMed Web of Science ®Google Scholar
• Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000;1:31-9
   PubMed Web of Science ®Google Scholar
• Giebel B, Corbeil D, Beckmann J, et al. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood 2004;104:2332-8
   PubMed Web of Science ®Google Scholar
• Florek M, Bauer N, Janich P, et al. Prominin-2 is a cholesterol-binding protein associated with apical and basolateral plasmalemmal protrusions in polarized epithelial cells and released into urine. Cell Tissue Res 2007;328:31-47
   PubMed Web of Science ®Google Scholar
• Kosodo Y, Röper K, Haubensak W, et al. Asymmetric distribution of the apical plasma membrane during neurogenic divisions of mammalian neuroepithelial cells. EMBO J 2004;23:2314-24
   PubMed Web of Science ®Google Scholar
• Bauer N, Fonseca AV, Florek M, et al. New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs 2008;188:127-38
   PubMed Web of Science ®Google Scholar
• Maw MA, Corbeil D, Koch J, et al. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 2000;9:27-34
   PubMed Web of Science ®Google Scholar
• Jaszai J, Fargeas CA, Florek M, et al. Focus on molecules: prominin-1 (CD133). Exp Eye Res 2007;85:585-86
   PubMed Web of Science ®Google Scholar
• Varnum-Finney B, Xu L, Brashem-Stein C, et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med 2000;6:1278-81
   PubMed Web of Science ®Google Scholar
• Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-54
   PubMed Web of Science ®Google Scholar
• Lindsell CE, Boulter J, Disibio G, et al. Expression patterns of Jagged, Delta1, Notch1, Notch2, and Notch3 genes identify ligand-receptor pairs that may function in neural development. Mol Cell Neurosci 1996;8:14-27
   PubMed Web of Science ®Google Scholar
• Kasper M, Regl G, Frischauf AM, et al. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer 2006;42:437-45
   PubMed Web of Science ®Google Scholar
• Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006;103:18261-66
   PubMed Web of Science ®Google Scholar
• Wong DJ, Liu H, Ridky TW, et al. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008;2:333-44
   PubMed Web of Science ®Google Scholar
• Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-34
   PubMed Web of Science ®Google Scholar
• Wang J, Wang H, Li Z, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE 2008;3(11):e3769, published online 20 November 2008, doi:10.1371/journal.pone.0003769
   PubMed Web of Science ®Google Scholar
• Stiles B, Groszer M, Wang S, et al. PTEN less means more. Dev Biol 2004;273:175-84
   PubMed Web of Science ®Google Scholar
• Dubrovska A, Kim S, Salamone RJ, et al. The role of PTEN/Akt/PI3K signalling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009;106:268-73
   PubMed Web of Science ®Google Scholar
• Wang S, Garcia AJ, Wu M, et al. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 2006;103:1480-85
   PubMed Web of Science ®Google Scholar
• Yi L, Zhou ZH, Ping YF, et al. Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. Mod Pathol 2007;20:1061-68
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60
   PubMed Web of Science ®Google Scholar
• Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133– cells, and the CD133 + sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007;67:1-5
   PubMed Web of Science ®Google Scholar
• Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003;100(25):15178-83
   PubMed Web of Science ®Google Scholar
• O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10
   PubMed Web of Science ®Google Scholar
• Bruno S, Bussolati B, Grange C, et al. CD133 + renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 2006;169:2223-35
   PubMed Web of Science ®Google Scholar
• Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007;120:1444-50
   PubMed Web of Science ®Google Scholar
• Suetsugu A, Nagaki M, Aoki H, et al. Characterization of CD133 + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006;351:820-24
   PubMed Web of Science ®Google Scholar
• Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008;62:1212-18
   PubMed Web of Science ®Google Scholar
• Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-14
   PubMed Web of Science ®Google Scholar
• Baba T, Convery PA, Matsumura N, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133 + ovarian cancer cells. Oncogene 2009;28:209-18
   PubMed Web of Science ®Google Scholar
• Olempska M, Eisenach PA, Ammerpohl O, et al. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 2007;6:92-7
   PubMed Web of Science ®Google Scholar
• Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007;43:935-46
   PubMed Web of Science ®Google Scholar
• Klein WM, Wu BP, Zhao S, et al. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007;20:102-7
   PubMed Web of Science ®Google Scholar
• Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med 2008;86:1025-32
   PubMed Web of Science ®Google Scholar
• Chiou SH, Kao CL, Chen YW, et al. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS ONE 2008;3:e2090, published online 7 May 2008, doi:10.1371/journal.pone.0002090
   PubMed Web of Science ®Google Scholar
• Ieta K, Tanaka F, Haraguchi N, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008;15(2):638-48
   PubMed Web of Science ®Google Scholar
• Maeda S, Shinchi H, Kurahara H, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor C expression in pancreatic cancer. Br J Cancer 2008;98:1389-97
   PubMed Web of Science ®Google Scholar
• Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100-9
   PubMed Web of Science ®Google Scholar
• Jooh KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastoma. Lab Invest 2008;88:808-15
   PubMed Web of Science ®Google Scholar
• Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008;122:761-68
   PubMed Web of Science ®Google Scholar
• Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133 + and CD133– metastatic colon cancer cells initiate tumors.J Clin Invest 2008;118:2111-20
   PubMed Web of Science ®Google Scholar
• Wu A, Wiesner S, Xiao J, et al. Expression of MHC-I and NK ligands on human CD133 + glioma cells: possible targets of immunotherapy. J Neurooncol 2007;83:121-31
   PubMed Web of Science ®Google Scholar
• Mehra N, Penning M, Maas J, et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 2006;12:4859-66
   PubMed Web of Science ®Google Scholar
• Lin EH, Hassan M, Li Y, et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 2007;110:534-42
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84
   PubMed Web of Science ®Google Scholar
• Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-34
   PubMed Web of Science ®Google Scholar
• Capper D, Gaiser T, Hartmann C, et al. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol 2009;117:445-56
   PubMed Web of Science ®Google Scholar
• Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65:4320-33
   PubMed Web of Science ®Google Scholar
• Kühnle M, Egger M, Müller C, et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 2009, published online, 26 January 2009, doi: 10.1021/jm8013822
   PubMed Web of Science ®Google Scholar
• Dai CL, Tiwari AK, Wu CP, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member2. Cancer Res 2008;68:7905-14
   PubMed Web of Science ®Google Scholar
• Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009;37:359-65
   PubMed Web of Science ®Google Scholar
• Griguer CE, Oliva CR, Gobin E, et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE 2009;3, published online 5 November 2008, doi:10.1371/journal.pone.0003655
   Google Scholar
• Wang C, Chen L, Hou Z, et al. Interactions between E2F1 and SirT1 regulate apoptosis response to DNA damage. Nat Cell Biol 2006;8:1025-31
   PubMed Web of Science ®Google Scholar
• Chang CJ, Hsu CC, Yung MC, et al. Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 2009;380:236-42
   PubMed Web of Science ®Google Scholar
• Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66:7445-52
   PubMed Web of Science ®Google Scholar
• Clement V, Sanchez P, de Tribolet N, et al. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007;17:165-72
   PubMed Web of Science ®Google Scholar
• Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibiton by Hedgehog pathway blockade. Science 2002;297:1559-61
   PubMed Web of Science ®Google Scholar
• Romer J, Kimura H, Magdaleno S. et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1 +/– p53–/– mice. Cell 2004;6:229-40
   Google Scholar
• Xie J, Johnson RL, Zhang X, et al. Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 1997;57:2369-72
   PubMed Web of Science ®Google Scholar
• Griffero F, Daga A, Marubbi D, et al. Different response of human glioma tumor-initiating cells to EGFR kinase inhibitors. J Biol Chem 2009;284:7138-48
   PubMed Web of Science ®Google Scholar
• Dillon RL, White DE, Muller WJ. The phosphatidyl inositol-3-kinase signalling network: implications for human breast cancer. Oncogene 2007;26:1338-45
   PubMed Web of Science ®Google Scholar
• Martelli AM, Nyåkern M, Tabellini G, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukaemia. Leukemia 2006;20:911-28
   PubMed Web of Science ®Google Scholar
• Grommes C, Landreth GE, Sastre M, et al. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor γ agonist treatment. Mol Pharmacol 2006;70:1524-33
   PubMed Web of Science ®Google Scholar
• Chearwae W, Bright JJ. PPARγ agonists inhibit growth and expansion of CD133 + brain tumor stem cells. Br J Cancer 2008;99:2044-53
   PubMed Web of Science ®Google Scholar
• Kubohara Y. Effects of differentiation-inducing factors of Dictyostelium discoideum on human leukaemia K562 cells: DIF-3 is the most potent anti-leukemic agent. Eur J Pharmacol 1999;381:57-62
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F, Sasaguri T. Drug development targeting the glycogen synthase kinase-3β (GSK-3β)-mediated signal transduction pathway: inhibitors of the Wnt/β-catenin signaling pathway as novel anticancer drugs. J Pharmacol Sci 2009;109(2):179-83
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Ye Y, et al. Antibody–drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21
   PubMed Web of Science ®Google Scholar
• Wu A, Wiesner S, Xiao J, et al. Expression of MHC-I and NK ligands on human CD133 + glioma cells: possible targets of immunotherapy. J Neurooncol 2007;83:121-31
   PubMed Web of Science ®Google Scholar
• Schwemmlein M, Peipp M, Barbin K, et al. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. Br J Haematol 2006;133(2):141-51
   PubMed Web of Science ®Google Scholar